NEW YORK, Feb. 1, 2017 /PRNewswire/ -- Commoditization and Competition
The generic injectable drug segment is a rapidly evolving and highly competitive market that lacks a true data compass to assist decision makers in mapping strategies for success in this segment. Attempting to determine the optimal time to file an ANDA application is a process that can be worth significant profits for first-to-filers.
But it is a process that is marked by little in the way of analytical decision support and in which litigation has become a staple defensive mechanism for both the filer and the branded drug owner. There are 235 distinct APIs for which there is at least one approved generic injectable ANDA. These 235 APIs account for 1,182 approved ANDAs. Including all approved doses, the current universe of generic injectables consists of 1,726 unique injectable products. These products are currently marketed and supplied by slightly less than one hundred companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.
Market-driven Product Strategies
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumercompatible form of packaging and application.
'This report is a comprehensive evaluation and analysis of the products and participants in this evolving segment of the injectable drug sector. It is designed to provide drug product decision makers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, disease segments, and commercial opportunities for generic injectables. Provider organization business managers, healthcare administrators and investors will also benefit from this study.'
What You Will Learn
• Provides detailed analysis of generic drugs supplied as injectables and assesses key market segments, market dynamics and potential product opportunities
• Presents the competitive picture for generic injectables in two dozen drug classes
• Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
• Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
• Assesses the market presence and product position of the top twenty-four generic injectables suppliers
• Evaluates the impact of economic, technology, and regulatory factors
Who Should Read this Report
• Drug Developers
• Device Suppliers
• Clinical Trial Mgmt
• Pharma Managers
• Biotech Managers
• Drug Marketers
• Industry Strategists
• Financial Analysts
• Management Consultants
• Clinical Managers
• Drug Distributors
• Pharma Regulators
• FDA Consultants
• Managed Care Managers
Read the full report: http://www.reportlinker.com/p04665929-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
Contact Clare: email@example.com
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-generic-injectables-market-300400694.html